6th Aug 2020 14:58
Avacta Group PLC - Wetherby, England-based developer of Affimer biotherapeutics and reagents - Appoints BBI Solutions, part of BBI Group, to manufacture the saliva-based rapid SARS-CoV-2 antigen test that is being developed with Cytiva. Manufacturing agreement between Avacta and BBI comprises the accelerated development and validation of a scaled-up manufacturing process that has the potential to ramp up to a production capacity of millions of tests per month
Current stock price: 137.30 pence
Year-to-date change: up more than 100%; 17.25p on December 31
By Tapan Panchal; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Avacta Group